Bitsori Maria, Maraki Sofia, Galanakis Emmanouil
Department of Paediatrics, University Hospital of Heraklion, Crete, Greece.
Pediatr Nephrol. 2014 Jun;29(6):1053-8. doi: 10.1007/s00467-013-2719-x. Epub 2013 Dec 21.
The aim of this study was to identify long-term resistance trends of uropathogens and determine the effect of prophylaxis in a pediatric patient population.
A total of 638 uropathogens were isolated from urine samples collected from children hospitalized for urinary tract infection during the 12-year study period (1997-2008) and analyzed.
The most frequent uropathogen identified was Escherichia coli (69 %), followed by Klebsiella spp. (9.7 %), Pseudomonas aeruginosa (6.7 %), Enterococcus spp. (5.6 %), and Proteus spp. (4.4 %). High resistance rates were observed for common agents used for empiric treatment, such as amoxicillin, cotrimoxazole, and ceftriaxone. Resistance increased over time for nitrofurantoin, ceftriaxone, and piperacilin-tazobactam (chi-square for trend p < 0.0002, p < 0.0034 and p < 0.014, respectively) and decreased for cefuroxime (p < 0.016) and gentamicin (p < 0.014). The use of prophylaxis was related to an increased proportion of non-E. coli pathogens (46.9 vs. 26.9 %; odds ratio 2.4, 95 % confidence interval 1.61-3.55; p < 0.0001), as well as to increased resistance of non-E. coli pathogens, and was a major risk factor associated with resistance to amoxiclav (p < 0.005), cotrimoxazole (p < 0.0001), cefuroxime (p < 0.0001), ceftriaxone (p < 0.0001), gentamicin (p < 0.0001), and nitrofurantoin (p < 0.0001).
Our findings point to considerable changes in the long-term resistance patterns of uropathogens and an association of prophylaxis with resistance. Our results suggest the need for continuous surveillance, re-evaluation of empiric regimens and further assessment of the role of prophylaxis in the treatment of urinary tract infection.
本研究旨在确定尿路病原体的长期耐药趋势,并确定预防措施在儿科患者群体中的效果。
在为期12年的研究期间(1997 - 2008年),从因尿路感染住院的儿童尿液样本中分离出638株尿路病原体并进行分析。
鉴定出的最常见尿路病原体是大肠杆菌(69%),其次是克雷伯菌属(9.7%)、铜绿假单胞菌(6.7%)、肠球菌属(5.6%)和变形杆菌属(4.4%)。观察到用于经验性治疗的常用药物,如阿莫西林、复方新诺明和头孢曲松,耐药率较高。呋喃妥因、头孢曲松和哌拉西林 - 他唑巴坦的耐药性随时间增加(趋势卡方检验p < 0.0002、p < 0.0034和p < 0.014),而头孢呋辛(p < 0.016)和庆大霉素(p < 0.014)的耐药性降低。预防措施的使用与非大肠杆菌病原体比例增加有关(46.9%对26.9%;比值比2.4,95%置信区间1.61 - 3.55;p < 0.0001),也与非大肠杆菌病原体耐药性增加有关,并且是与阿莫西林克拉维酸(p < 0.005)、复方新诺明(p < 0.0001)、头孢呋辛(p < 0.0001)、头孢曲松(p < 0.0001)、庆大霉素(p < 0.0001)和呋喃妥因(p < 0.0001)耐药相关的主要危险因素。
我们的研究结果表明尿路病原体的长期耐药模式有显著变化,且预防措施与耐药性有关。我们的结果提示需要持续监测、重新评估经验性治疗方案以及进一步评估预防措施在尿路感染治疗中的作用。